Gabapentinoids for oncologic pruritus: a retrospective cohort study
The Oncologist · 05.11.2026 · 31 (12)
DOI: 10.1093/oncolo/oyag431 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Oncologist, online erschienen am 28.10.2026. Verfasst von Alim Osman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States. Hauptthemen laut MEDLINE: Pruritus, Gabapentin, Neoplasms, Pregabalin. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pruritus is a debilitating symptom in oncologic patients which often leads to treatment interruptions or dose reductions and reduced quality of life. Gabapentinoids such as gabapentin and pregabalin approved for postherpetic neuralgia, partial seizures, neuropathic pain, and fibromyalgia have also demonstrated efficacy in treating non-oncologic forms of pruritus. We report on the safety and efficacy of gabapentinoids for oncologic pruritus. Patients and methods This was a single-center retrospective cohort study conducted at the Memorial Sloan Kettering Cancer Center (MSK). All patients from January 04, 2019 to January 8, 2024 prescribed gabapentinoids for oncologic pruritus were retrospectively identified.
Results
224 patients were included; the average age of the cohort was 63.2 ± 15 years and were mostly male (54%). Patients were treated for pruritus secondary to drug-induced causes (60.3%), malignancy/paraneoplastic (15.2%), cutaneous graft-versus-host disease (13.4%), and other etiologies (11.2%). Pregabalin was more frequently prescribed than gabapentin (80.8% vs. 19.2%). Ninety percent of patients (n = 202) experienced ≥1 grade improvement in CTCAE grade, at a median dosage 50 mg and 300 mg for pregabalin and gabapentin, respectively. The median time to patient-reported initial symptom improvement was 18.5 days. The median time to the documented ≥1 CTCAE grade improvement was 3.5 months (95% CI, 3.0-4.7), with no significant difference observed between pruritus etiologies. Adverse events were reported in 14.7% of patients, most commonly sedation (8.5%). Only three patients discontinued gabapentinoids due to adverse events.
Conclusion
Our results demonstrate that gabapentinoids are a safe and effective way to treat oncologic pruritus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States.
- Weill Cornell Medical College, New York, NY 10065, United States.
- Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States.
- Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States.
- Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States.
ORCID-Profile: Alim Osman, Ian Nykaza, Sarah L Spaulding, Lavanya Mittal, Allison Gordon, Cesar A Virgen, Doris M Ponce, Jodi Victoria Mones, Alina Markova
Zitieren
APA
Osman, A., Nykaza, I., Spaulding, S. L., Dusza, S. W., Mittal, L., Gordon, A., Geller, S., Virgen, C. A., Rotemberg, V., Ponce, D. M., Singh, J. C., Mones, J. V., & Markova, A. (2026). Gabapentinoids for oncologic pruritus: a retrospective cohort study. The Oncologist, 31(12). https://doi.org/10.1093/oncolo/oyag431
Vancouver
Osman A, Nykaza I, Spaulding SL, Dusza SW, Mittal L, Gordon A, et al. Gabapentinoids for oncologic pruritus: a retrospective cohort study. The Oncologist. 2026;31(12). doi:10.1093/oncolo/oyag431
BibTeX
@article{Osman2026,
author = {Osman, Alim and Nykaza, Ian and Spaulding, Sarah L and Dusza, Stephen W and Mittal, Lavanya and Gordon, Allison and Geller, Shamir and Virgen, Cesar A and Rotemberg, Veronica and Ponce, Doris M and Singh, Jasmeet C and Mones, Jodi Victoria and Markova, Alina},
title = {Gabapentinoids for oncologic pruritus: a retrospective cohort study},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {12},
doi = {10.1093/oncolo/oyag431}
}
EUVIMED